Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Nexium Marketing Draws FTC Scrutiny; DoJ Looking At Prilosec 

Executive Summary

The Federal Trade Commission is investigating AstraZeneca's marketing of the omeprazole follow-on product Nexium

You may also be interested in...



AstraZeneca subpoenaed

The Boston U.S. Attorney's office issues subpoena to AstraZeneca as part of an investigation related to sales and marketing practices to a physician's office in Worcester, Mass., company says in a Securities & Exchange Commission 1filing. This investigation is separate from another Boston U.S. Attorney investigation into Prilosec promotions to New England Medical Center (2"The Pink Sheet" March 3, 2003, p. 3)...

AstraZeneca subpoenaed

The Boston U.S. Attorney's office issues subpoena to AstraZeneca as part of an investigation related to sales and marketing practices to a physician's office in Worcester, Mass., company says in a Securities & Exchange Commission 1filing. This investigation is separate from another Boston U.S. Attorney investigation into Prilosec promotions to New England Medical Center (2"The Pink Sheet" March 3, 2003, p. 3)...

Nexium-Style Products Encourage Price Competition, FDA’s McClellan Says

The availability of follow-on products like AstraZeneca's Nexium can encourage price competition within a therapeutic class, FDA Commissioner McClellan told the National Press Club Aug. 8 in Washington, D.C

Related Content

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel